Anti-Mouse IL-6R Antibody (15A7)
Based on 1 publication(s) in Google Scholar
Anti-Mouse IL-6R Antibody (15A7) is a rat-derived anti-mouse IL-6R IgG2b κ type antibody inhibitor. Anti-Mouse IL-6R Antibody (15A7) blocks IL-6 binding to IL-6Rα and inhibits both IL-6 classic and trans-signaling. Anti-Mouse IL-6R Antibody (15A7) can be used for the researches of cancer and inflammation, such as triple-negative breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.79%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse IL-6R Antibody (15A7)
More
Biological Activity
Description
Isotype
Rat IgG2b kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
IL-6R
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse IL-6R Antibody (15A7) (2.5 mg/kg, i.v., semiweekly for 3 weeks) shows anti-tumor effect in triple-negative breast cancer mice models[2].
Anti-Mouse IL-6R Antibody (15A7) (10 mg/kg, i.p., after 6 h of IL-1α injection) efficiently crosses the maternal–foetal interface, restores foetal growth, and dampens foetal inflammation in pregnant IL-1α-induced inflammation mice models[3].
Anti-Mouse IL-6R Antibody (15A7) (0.5-3 mg, s.c., 24 h before T1033C2 injection) inhibits tumor growth and increases survival rate in T1033C2 plasmacytoma mice models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Triple-negative breast cancer mice models[2]
-
Dosage:2.5 mg/kg
-
Administration:Intravenously injection, semiweekly for 3 weeks
-
Result:Increased survival rate.
Inhibited postsurgical lung nodules metastasis.
Reduced CD163(+) M2 macrophage and Foxp3(+) Treg infiltration.
-
Animal Model:IL-1α-induced systemic inflammation mice models (pregnant)[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneally injection, after 6 h of IL-1α injection
-
Result:Could be detected in the intraamniotic space.
Prevented the IL-1α-induced expression of Ccl3, Nlrp3, Il12a, and Lrg1 in the placenta.
Decreased TNF and IL-6 levels.
Prevented the IL-1α-driven dysregulation of Il1a, Il1b, Tnf, and Lrg1 in the foetal brain, P2rx7 in the foetal lung, and S100a9 in the foetal intestine.
Protected against IL-1α-induced foetal growth restriction.
Improved adverse neonatal outcomes induced by intra-amniotic IL-1α.
Restored IL-1α-induced neonatal gut immune-microbiome alterations.
-
Animal Model:T1033C2 plasmacytoma mice models[4]
-
Dosage:0.5-3 mg
-
Administration:Subcutaneously injection, 24 h before T1033C2 injection
-
Result:Showed protection rate of 60%.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo blocking of IL-6/IL-6R signaling; in vitro blocking of IL-6R signaling
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse IL-6R Antibody (15A7)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2026 Jun 8;44(6):1255-1269.e9. PMID: 42066761
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Romano M, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997 Mar;6(3):315-25. [Content Brief]
[2]. Haq ATA, et al. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer. Theranostics. 2024 Mar 3;14(5):2167-2189. [Content Brief]
[3]. Farias-Jofre M, et al. Blockade of IL-6R prevents preterm birth and adverse neonatal outcomes. EBioMedicine. 2023 Dec;98:104865. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse IL-6R Antibody (15A7) Related Classifications
HY-P990211 Related Classifications
Powered by Bioz